Sana Klinikum Offenbach

The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis (2021) Iking-Konert C, Wallmeier P, Arnold S, Adler S, De Groot K, Hellmich B, Hoyer BF, et al. Journal article AGO Algorithms for the Treatment of Breast Cancer: Update 2021 AGO-Algorithmen zur Behandlung von Brustkrebs: Update 2021 (2021) Schneeweiss A, Fasching P, Fehm T, Gerber B, Jackisch C, Loibl S, Schmidt M, et al. Journal article Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference (2021) Untch M, Fasching P, Brucker SY, Budach W, Denkert C, Haidinger R, Huober J, et al. Journal article, Review article Update Breast Cancer 2021 Part 2-Advanced Stages, Long-Term Consequences and Biomarkers (2021) Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching P, Fehm TN, Hartkopf AD, et al. Journal article, Review article Update Breast Cancer 2021 Part 1-Prevention and Early Stages (2021) Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching P, Fehm TN, et al. Journal article, Review article BACH1 and HIF1 alpha predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, et al. Conference contribution Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) Labidi-Galy SI, Schneeweiss A, Sinn HP, Blohmer JU, Romanens L, Zahm DM, Huober J, et al. Conference contribution Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, et al. Conference contribution AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article